DiaMedica Therapeutics Inc

Healthcare US DMAC

6.15USD
0.26(4.41%)

Last update at 2026-06-23T18:31:00Z

Day Range

5.786.25

LowHigh

52 Week Range

3.4810.42

LowHigh

Fundamentals

Previous Close 5.89
Market Cap345.93M
Volume126876
P/E Ratio-
Dividend Yield-%
EBITDA-34.35400M
Revenue TTM0.00000M
Revenue Per Share TTM-
Gross Profit TTM 0.00000M
Diluted EPS TTM-0.7

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Income before tax	-32.73800M	-24.41400M	-19.33800M	-13.64800M	-13.56400M
Minority interest	-	-	-	-	-
Net income	-32.76600M	-24.44400M	-19.38100M	-13.67600M	-13.59200M
Selling general administrative	9.78M	7.43M	7.96M	6.16M	4.88M
Selling and marketing expenses	-	0.19M	0.20M	-	-
Gross profit	-	-0.03900M	-0.03000M	-	-
Reconciled depreciation	0.04M	0.04M	0.03M	0.03M	0.02M
Ebit	-34.39700M	-26.68100M	-21.26700M	-14.00100M	-13.64600M
Ebitda	-34.35400M	-26.64200M	-21.23700M	-13.97600M	-13.62200M
Depreciation and amortization	0.04M	0.04M	0.03M	0.03M	0.02M
Non operating income net other	-	-	-	-	-
Operating income	-34.39700M	-26.68100M	-21.26700M	-14.00100M	-13.64600M
Other operating expenses	34.40M	26.68M	21.27M	14.00M	13.65M
Interest expense	-	-	-	0.35M	0.08M
Tax provision	0.03M	0.03M	0.03M	0.03M	0.03M
Interest income	-	-	-	-	-
Net interest income	-	-	-	-	-
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	0.03M	0.03M	0.04M	0.03M	0.03M
Total revenue	0.00000M	0.00000M	0.00000M	0.00000M	0.00000M
Total operating expenses	34.40M	26.68M	21.27M	14.00M	13.65M
Cost of revenue	-	0.04M	0.03M	-	-
Total other income expense net	1.66M	2.27M	1.93M	0.35M	0.08M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-32.76600M	-24.44400M	-17.97100M	-13.67600M	-13.59200M
Net income applicable to common shares	-	-	-	-	-13.59200M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total assets	61.37M	46.34M	54.16M	34.40M	45.55M
Intangible assets	-	-	-	-	-
Earning assets	-	-	-	-	-
Other current assets	0.48M	0.23M	0.41M	0.25M	0.08M
Total liab	5.26M	5.63M	3.10M	2.57M	1.53M
Total stockholder equity	56.11M	40.72M	51.06M	31.83M	44.02M
Deferred long term liab	-	-	-	-	-
Other current liab	3.54M	4.35M	1.78M	1.36M	0.97M
Common stock	-	-	-	-	-
Capital stock	0.00000M	0.00000M	0.00000M	0.00000M	0.00000M
Retained earnings	-172.76800M	-140.00200M	-115.55800M	-96.17700M	-82.50100M
Other liab	-	-	-	-	-
Good will	-	-	-	-	-
Other assets	-	-	0.00000M	-	-
Cash	15.65M	3.02M	4.54M	4.73M	4.71M
Cash and equivalents	-	-	-	-	-
Total current liabilities	5.13M	5.39M	2.79M	2.17M	1.52M
Current deferred revenue	-	-	-	-	-
Net debt	-15.40700M	-2.68500M	-4.14300M	-4.25900M	-4.65500M
Short term debt	0.11M	0.10M	0.08M	0.07M	0.05M
Short long term debt	-	-	-	-	-
Short long term debt total	0.24M	0.34M	0.40M	0.47M	0.05M
Other stockholder equity	228.83M	180.70M	166.61M	128.08M	126.58M
Property plant equipment	-	-	-	0.56M	0.11M
Total current assets	60.63M	44.61M	53.67M	33.84M	45.44M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	-	-	44.02M
Short term investments	44.24M	41.12M	48.35M	28.77M	40.41M
Net receivables	0.26M	0.24M	0.37M	0.08M	0.13M
Long term debt	-	-	-	-	-
Inventory	-	-	-	-	0.11M
Accounts payable	1.48M	0.94M	0.93M	0.73M	0.51M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	0.05M	0.02M	0.00600M	-0.07400M	-0.05100M
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	0.40M	1.31M	-0.00000M	-	-40.40500M
Deferred long term asset charges	-	-	-	-	-
Non current assets total	0.74M	1.74M	0.48M	0.56M	0.11M
Capital lease obligations	0.24M	0.34M	0.40M	0.47M	0.05M
Long term debt total	-	-	-	-	-

Breakdown	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Investments	-2.15200M	8.56M	-19.69900M	11.54M	-20.51700M
Change to liabilities	-	-	-	0.00000M	-0.59000M
Total cashflows from investing activities	-2.19200M	8.56M	-18.29900M	-	-20.53700M
Net borrowings	-0.01000M	-0.00900M	-0.00600M	-0.00600M	-0.00600M
Total cash from financing activities	43.88M	11.99M	36.84M	-0.00600M	30.09M
Change to operating activities	-	-	-	0.31M	-0.08100M
Net income	-32.76600M	-24.44400M	-19.38100M	-13.67600M	-13.59200M
Change in cash	12.62M	-1.51800M	-0.18500M	0.02M	-2.70200M
Begin period cash flow	3.02M	4.54M	4.73M	4.71M	7.41M
End period cash flow	15.65M	3.02M	4.54M	4.73M	4.71M
Total cash from operating activities	-29.06200M	-22.07600M	-18.72800M	-11.51100M	-12.25200M
Issuance of capital stock	43.28M	11.75M	36.85M	0.00000M	29.85M
Depreciation	-0.89900M	0.04M	0.03M	0.03M	0.02M
Other cashflows from investing activities	-	-	-	-	-
Dividends paid	-	-	-	-	-
Change to inventory	-	-	-	-	-
Change to account receivables	-0.02200M	0.13M	-0.28700M	0.05M	0.21M
Sale purchase of stock	-	-	-	-	-
Other cashflows from financing activities	-0.40000M	0.26M	-18.29900M	11.54M	0.24M
Change to netincome	-	-	-	1.55M	1.78M
Capital expenditures	0.04M	0.03M	0.02M	0.08M	0.02M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	0.68M	1.51M	0.09M	0.58M	-0.46100M
Stock based compensation	3.85M	2.08M	1.68M	1.50M	1.56M
Other non cash items	0.08M	-1.26800M	-1.15300M	0.05M	0.06M
Free cash flow	-29.10200M	-22.10100M	-18.75200M	-11.59200M	-12.27400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
DMAC DiaMedica Therapeutics Inc	0.26 4.41%	6.15	-	-	66.68	6.17	57.48	-0.9637
NVO Novo Nordisk A/S	0.94 2.04%	46.81	41.58	31.15	2.13	32.99	2.11	4.70
NONOF Novo Nordisk A/S	- -%	45.00	41.06	31.25	2.08	33.11	2.11	4.70
VRTX Vertex Pharmaceuticals Inc	2.93 0.63%	469.72	29.67	24.33	10.38	5.83	9.33	20.00
REGN Regeneron Pharmaceuticals Inc	5.28 0.86%	617.77	29.07	20.12	7.57	3.82	6.95	19.42

Reports Covered

View All

Profile

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DiaMedica Therapeutics Inc

301 Carlson Parkway, Minneapolis, MN, United States, 55305

763 496 5454
https://www.diamedica.com
Employees : 35

Key Executives

Name	Title	Year Born
Mr. Dietrich John Pauls MBA	Pres, CEO & Director	1971
Mr. Scott B. Kellen C.A.	CFO & Company Sec.	1965
Dr. Edward G. Calamai Ph.D.	Consulting Head of Manufacturing	NA
Dr. Kirsten L. Gruis M.D., M.S.	Chief Medical Officer	1973
Mr. Dominic R. Cundari	Chief Commercial Officer	1951
Ms. Julie VanOrsdel Daves CCRP	Sr. VP of Clinical Devel. Operations	NA
Mr. Dietrich John Pauls MBA	President, CEO & Director	1971
Mr. Scott Kellen C.P.A.	CFO & Corporate Secretary	1965
Dr. Kirsten L. Gruis M.D., M.S.	Independent Consultant	1973
Ms. Julie VanOrsdel Daves CCRP	Senior Vice President of Clinical Development Operations	1974

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.